相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Acute Treatment Effects on GFR in Randomized Clinical Trials of Kidney Disease Progression
Brendon L. Neuen et al.
JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY (2022)
Safety and efficacy of dapagliflozin in patients with focal segmental glomerulosclerosis: a prespecified analysis of the dapagliflozin and prevention of adverse outcomes in chronic kidney disease (DAPA-CKD) trial
David C. Wheeler et al.
NEPHROLOGY DIALYSIS TRANSPLANTATION (2022)
Cardiac and Kidney Benefits of Empagliflozin in Heart Failure Across the Spectrum of Kidney Function Insights From EMPEROR-Reduced
Faiez Zannad et al.
CIRCULATION (2021)
Efficacy of Dapagliflozin on Renal Function and Outcomes in Patients With Heart Failure With Reduced Ejection Fraction Results of DAPA-HF
Pardeep S. Jhund et al.
CIRCULATION (2021)
A pre-specified analysis of the DAPA-CKD trial demonstrates the effects of dapagliflozin on major adverse kidney events in patients with IgA nephropathy
David C. Wheeler et al.
KIDNEY INTERNATIONAL (2021)
Cardiac, renal, and metabolic effects of sodium-glucose co-transporter 2 inhibitors: a position paper from the European Society of Cardiology ad-hoc task force on sodium-glucose co-transporter 2 inhibitors
William G. Herrington et al.
EUROPEAN JOURNAL OF HEART FAILURE (2021)
Empagliflozin in Heart Failure with a Preserved Ejection Fraction
Stefan D. Anker et al.
NEW ENGLAND JOURNAL OF MEDICINE (2021)
Net effects of sodium-glucose co-transporter-2 inhibition in different patient groups: a meta-analysis of large placebo-controlled randomized trials
Natalie Staplin et al.
ECLINICALMEDICINE (2021)
Choice of endpoint in kidney outcome trials: considerations from the EMPA-REG OUTCOME® trial
Vlado Perkovic et al.
NEPHROLOGY DIALYSIS TRANSPLANTATION (2020)
Kidney disease trials for the 21st century: innovations in design and conduct
William G. Herrington et al.
NATURE REVIEWS NEPHROLOGY (2020)
The tubular hypothesis of nephron filtration and diabetic kidney disease
Volker Vallon et al.
NATURE REVIEWS NEPHROLOGY (2020)
Different eGFR Decline Thresholds and Renal Effects of Canagliflozin: Data from the CANVAS Program
Megumi Oshima et al.
JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY (2020)
International consensus definitions of clinical trial outcomes for kidney failure: 2020
Adeera Levin et al.
KIDNEY INTERNATIONAL (2020)
The dapagliflozin and prevention of adverse outcomes in chronic kidney disease (DAPA-CKD) trial: baseline characteristics
David C. Wheeler et al.
NEPHROLOGY DIALYSIS TRANSPLANTATION (2020)
Cardiovascular and Renal Outcomes with Empagliflozin in Heart Failure
Milton Packer et al.
NEW ENGLAND JOURNAL OF MEDICINE (2020)
Dapagliflozin in Patients with Chronic Kidney Disease
Hiddo J. L. Heerspink et al.
NEW ENGLAND JOURNAL OF MEDICINE (2020)
Effects of dapagliflozin on major adverse kidney and cardiovascular events in patients with diabetic and non-diabetic chronic kidney disease: a prespecified analysis from the DAPA-CKD trial
David C Wheeler et al.
Lancet Diabetes & Endocrinology (2020)
Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy
V. Perkovic et al.
NEW ENGLAND JOURNAL OF MEDICINE (2019)
Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction
J. J. V. McMurray et al.
NEW ENGLAND JOURNAL OF MEDICINE (2019)
SGLT2 inhibitors for the prevention of kidney failure in patients with type 2 diabetes: a systematic review and meta-analysis
Brendan L. Neuen et al.
LANCET DIABETES & ENDOCRINOLOGY (2019)
Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes
S. D. Wiviott et al.
NEW ENGLAND JOURNAL OF MEDICINE (2019)
The potential for improving cardio-renal outcomes by sodium-glucose co-transporter-2 inhibition in people with chronic kidney disease: a rationale for the EMPA-KIDNEY study
William G. Herrington et al.
CLINICAL KIDNEY JOURNAL (2018)
Challenges in conducting clinical trials in nephrology: conclusions from a Kidney Disease-Improving Global Outcomes (KDIGO) Controversies Conference
Colin Baigent et al.
KIDNEY INTERNATIONAL (2017)
Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes
Bruce Neal et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
Empagliflozin and Kinetics of Renal Glucose Transport in Healthy Individuals and Individuals With Type 2 Diabetes
Hussein Al-Jobori et al.
DIABETES (2017)
Association between obesity and glomerular hyperfiltration: the confounding effect of smoking and sodium and protein intakes
Adam Ogna et al.
EUROPEAN JOURNAL OF NUTRITION (2016)
Kidney function and sudden cardiac death in the community: The Atherosclerosis Risk in Communities (ARIC) Study
Takeki Suzuki et al.
AMERICAN HEART JOURNAL (2016)
Enhancing clinical evidence by proactively building quality into clinical trials
Ann Meeker-O'Connell et al.
CLINICAL TRIALS (2016)
Shift to Fatty Substrate Utilization in Response to Sodium-Glucose Cotransporter 2 Inhibition in Subjects Without Diabetes and Patients With Type 2 Diabetes
Ele Ferrannini et al.
DIABETES (2016)
Empagliflozin and Progression of Kidney Disease in Type 2 Diabetes
Christoph Wanner et al.
NEW ENGLAND JOURNAL OF MEDICINE (2016)
Impact of renal function on the effects of LDL cholesterol lowering with statin-based regimens: a meta-analysis of individual participant data from 28 randomised trials
William G. Herrington et al.
LANCET DIABETES & ENDOCRINOLOGY (2016)
Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes
Bernard Zinman et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Evaluating the Contribution of the Cause of Kidney Disease to Prognosis in CKD: Results From the Study of Heart and Renal Protection (SHARP)
Richard Haynes et al.
AMERICAN JOURNAL OF KIDNEY DISEASES (2014)
GFR Decline as an End Point for Clinical Trials in CKD: A Scientific Workshop Sponsored by the National Kidney Foundation and the US Food and Drug Administration
Andrew S. Levey et al.
AMERICAN JOURNAL OF KIDNEY DISEASES (2014)
Canagliflozin: Effects in Overweight and Obese Subjects Without Diabetes Mellitus
Harold E. Bays et al.
OBESITY (2014)
Chronic kidney disease: global dimension and perspectives
Vivekanand Jha et al.
LANCET (2013)
Blood pressure lowering and major cardiovascular events in people with and without chronic kidney disease: meta-analysis of randomised controlled trials
L. Agodoa et al.
BMJ-BRITISH MEDICAL JOURNAL (2013)
Associations between Kidney Function and Subclinical Cardiac Abnormalities in CKD
Meyeon Park et al.
JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY (2012)
Associations of kidney disease measures with mortality and end-stage renal disease in individuals with and without diabetes: a meta-analysis
Caroline S. Fox et al.
LANCET (2012)
Risk of coronary events in people with chronic kidney disease compared with those with diabetes: a population-level cohort study
Marcello Tonelli et al.
LANCET (2012)
Glomerular hyperfiltration: definitions, mechanisms and clinical implications
Imed Helal et al.
NATURE REVIEWS NEPHROLOGY (2012)
A New Equation to Estimate Glomerular Filtration Rate
Andrew S. Levey et al.
ANNALS OF INTERNAL MEDICINE (2009)
Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy
BM Brenner et al.
NEW ENGLAND JOURNAL OF MEDICINE (2001)
Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes
EJ Lewis et al.
NEW ENGLAND JOURNAL OF MEDICINE (2001)
Angiotensin-converting enzyme inhibitors and progression of nondiabetic renal disease - A meta-analysis of patient-level data
TH Jafar et al.
ANNALS OF INTERNAL MEDICINE (2001)
分享论文
